Revolution Medicines D
D
RVMD
172.280
USD
-4.01
(-2.27%)
Post Trading·172.020USD-0.260(-0.15%)
Last updated: · Delayed 15 min
Revolution Medicines cash on hand 2017–2026What is a balance sheet? The balance sheet lists what a company owns (assets), what it owes (liabilities) and what is left for its shareholders (equity) on one date.
Revolution Medicines had 3.65B USD in cash and short-term investments on 30 September 2026, up 89.0% on a year before. At the end of fiscal year 2025 it had 2.03B USD.
Last updated 8 Nov 2026 · Next report 24 Feb 2027
Cash on hand
Growth
| Fiscal year | Period ending | Cash on hand | Growth | Total debt | Net cash |
|---|---|---|---|---|---|
| Latest quarter | 30 Sept 2026 | 3.65B | +89.04% | 639.10M | 3.01B |
| FY2025 | 31 Dec 2025 | 2.03B | -11.52% | 158.70M | 1.87B |
| FY2024 | 31 Dec 2024 | 2.29B | +23.55% | 135.84M | 2.15B |
| FY2023 | 31 Dec 2023 | 1.85B | +187.31% | 87.94M | 1.77B |
| FY2022 | 31 Dec 2022 | 644.94M | +11.76% | 64.21M | 580.74M |
| FY2021 | 31 Dec 2021 | 577.05M | +30.93% | 66.63M | 510.42M |
| FY2020 | 31 Dec 2020 | 440.74M | +259.03% | 32.66M | 408.08M |
| FY2019 | 31 Dec 2019 | 122.76M | +76.41% | 0.00 | 122.76M |
| FY2018 | 31 Dec 2018 | 69.59M | +666.45% | 147.00K | 69.44M |
| FY2017 | 31 Dec 2017 | 9.08M | — | 0.00 | 9.08M |
| Quarter | Period ending | Cash on hand | Growth on a year before | Total debt | Net cash |
|---|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 3.65B | +89.04% | 639.10M | 3.01B |
| Q2 FY2026 | 30 Jun 2026 | 3.94B | +84.26% | 641.93M | 3.30B |
| Q1 FY2026 | 31 Mar 2026 | 1.91B | -9.25% | 437.27M | 1.47B |
| Q4 FY2025 | 31 Dec 2025 | 2.03B | -11.52% | 158.70M | 1.87B |
| Q3 FY2025 | 30 Sept 2025 | 1.93B | +24.66% | 158.46M | 1.77B |
| Q2 FY2025 | 30 Jun 2025 | 2.14B | +34.35% | 132.79M | 2.00B |
| Q1 FY2025 | 31 Mar 2025 | 2.10B | +23.43% | 134.34M | 1.97B |
| Q4 FY2024 | 31 Dec 2024 | 2.29B | +23.55% | 135.84M | 2.15B |
| Q3 FY2024 | 30 Sept 2024 | 1.55B | +90.54% | 86.71M | 1.46B |
| Q2 FY2024 | 30 Jun 2024 | 1.59B | +74.90% | 87.41M | 1.50B |
| Q1 FY2024 | 31 Mar 2024 | 1.70B | +87.24% | 88.03M | 1.62B |
| Q4 FY2023 | 31 Dec 2023 | 1.85B | +187.31% | 87.94M | 1.77B |
| Q3 FY2023 | 30 Sept 2023 | 813.20M | +24.15% | 62.85M | 750.35M |
| Q2 FY2023 | 30 Jun 2023 | 909.49M | +97.10% | 63.26M | 846.23M |
| Q1 FY2023 | 31 Mar 2023 | 909.80M | +75.38% | 63.60M | 846.20M |
| Q4 FY2022 | 31 Dec 2022 | 644.94M | +11.76% | 64.21M | 580.74M |
| Q3 FY2022 | 30 Sept 2022 | 655.01M | +7.62% | 65.20M | 589.81M |
| Q2 FY2022 | 30 Jun 2022 | 461.43M | -28.61% | 64.95M | 396.48M |
| Q1 FY2022 | 31 Mar 2022 | 518.75M | -23.89% | 65.91M | 452.84M |
| Q4 FY2021 | 31 Dec 2021 | 577.05M | +30.93% | 66.63M | 510.42M |
| Q3 FY2021 | 30 Sept 2021 | 608.66M | +30.57% | 31.79M | 576.87M |
| Q2 FY2021 | 30 Jun 2021 | 646.32M | +98.60% | 32.49M | 613.83M |
| Q1 FY2021 | 31 Mar 2021 | 681.59M | +95.89% | 31.99M | 649.60M |
| Q4 FY2020 | 31 Dec 2020 | 440.74M | +259.03% | 32.66M | 408.08M |
| Q3 FY2020 | 30 Sept 2020 | 466.14M | +242.03% | 33.38M | 432.76M |
| Q2 FY2020 | 30 Jun 2020 | 325.45M | — | 34.06M | 291.38M |
| Q1 FY2020 | 31 Mar 2020 | 347.95M | +400.03% | 10.84M | 337.11M |
| Q4 FY2019 | 31 Dec 2019 | 122.76M | +76.41% | 0.00 | 122.76M |
| Q3 FY2019 | 30 Sept 2019 | 136.29M | — | 157.00K | 136.13M |
| Q1 FY2019 | 31 Mar 2019 | 69.59M | — | 0.00 | 69.59M |
| Q4 FY2018 | 31 Dec 2018 | 69.59M | — | 147.00K | 69.44M |
Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.
See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Total debt,Free cash flow,Balance sheet
Common questions about Revolution Medicines's cash
Source: Financial Modeling PrepVerified against SEC filings